- Home
- BQ vs VIVS Comparison
BQ vs VIVS Comparison
Compare BQ & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BQ | VIVS |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | China | United States |
| Employees | N/A | 9 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 4.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BQ | VIVS |
|---|---|---|
| Price | $1.16 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.6K | 67.5K |
| Earning Date | 01-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $1.42 |
| 52 Week High | $72.74 | $5.30 |
Technical Indicators
Market Signals| Indicator | BQ | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 39.80 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.40 | $2.11 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 32.35 | 1.96 |
Price Performance
Historical ComparisonAbout BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.